In This Article:
As the European markets experience a modest upswing, with France's CAC 40 Index gaining 0.48%, investor attention is increasingly focused on growth opportunities amid anticipated interest rate adjustments by the European Central Bank. In this environment, companies with high insider ownership often signal strong internal confidence and alignment with shareholder interests, making them compelling considerations for those looking to capitalize on potential growth within the French market.
Top 10 Growth Companies With High Insider Ownership In France
| Name | Insider Ownership | Earnings Growth |
| Groupe OKwind Société anonyme (ENXTPA:ALOKW) | 20.6% | 36% |
| VusionGroup (ENXTPA:VU) | 13.4% | 81.7% |
| Icape Holding (ENXTPA:ALICA) | 30.2% | 33.9% |
| Arcure (ENXTPA:ALCUR) | 21.4% | 26.6% |
| STIF Société anonyme (ENXTPA:ALSTI) | 16.4% | 22.9% |
| La Française de l'Energie (ENXTPA:FDE) | 19.9% | 31.9% |
| S.M.A.I.O (ENXTPA:ALSMA) | 17.4% | 35.2% |
| Adocia (ENXTPA:ADOC) | 11.7% | 64% |
| Munic (ENXTPA:ALMUN) | 27.1% | 174.1% |
| MedinCell (ENXTPA:MEDCL) | 15.8% | 93.9% |
Let's review some notable picks from our screened stocks.
Exclusive Networks
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Exclusive Networks SA is a global cybersecurity specialist focusing on digital infrastructure, with a market cap of €2.14 billion.
Operations: The company's revenue segments are divided into APAC (€480 million), EMEA (€4.19 billion), and Americas (€705 million).
Insider Ownership: 13.1%
Exclusive Networks is experiencing significant insider ownership, with 66.7% held by Permira and founder Olivier Breittmayer. The company is set to be taken private in a €2.2 billion deal by Clayton, Dubilier & Rice and Permira, offering a 34.4% premium on its share price. While earnings are forecast to grow significantly at 33.5% annually, profit margins have decreased from last year, highlighting both growth potential and operational challenges.
MedinCell
Simply Wall St Growth Rating: ★★★★★☆
Overview: MedinCell S.A. is a pharmaceutical company based in France that focuses on developing long-acting injectables across various therapeutic areas, with a market cap of €465.98 million.
Operations: The company generates its revenue primarily from its Pharmaceuticals segment, which amounted to €11.95 million.
Insider Ownership: 15.8%
MedinCell showcases strong growth potential with forecasted annual revenue growth of 46.2%, significantly outpacing the French market. Recent strategic collaborations, including a $35 million upfront payment from AbbVie, bolster its innovative long-acting injectable technology platform. The company is expected to become profitable within three years despite negative shareholder equity and trades at 88.3% below estimated fair value. Insider ownership remains high following governance changes, enhancing alignment with shareholder interests amidst executive restructuring and index inclusion milestones.